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ABSTRACT
BIOMIMETIC SENSOR FOR IN-VIVO APPLICATIONS
by
Daya I. Sooryadas
The development of sensitive specific devices (e.g., molecular sensors) for the detection,
diagnosis and monitoring of diseases, drug discovery, environmental detection of
pollutants and/or biological agents has been an active area of research. A molecular
sensor is a biomolecule or biomimetic molecule that performs two distinct functions in
detecting target molecules. The sensor molecule recognizes a target molecule and
specifically binds to it. This specific binding generates a signal in response to the event of
target binding that can be then detected. The long term vision of this thesis research work
is to develop a specific recognition ligand for detecting proteins in living cell. A
molecular sensor for non-nucleic acid analytes (e.g., proteins, peptides, drugs, hormones)
can be designed and demonstrated using molecular recognition and design
principles analogous in some ways to the molecular switch principles used in Molecular
Beacons invented by Dr. Kramer and Dr. Tyagi.
Conventionally, people have looked at nucleic acids and antibodies used as
nucleic acid recognizing nucleic acid and antigen recognizing antibody. Nucleic acids
have protein binding capabilities i.e. they can act as aptamers having same design
construct as molecular beacons. Aptamer nucleic acids act as antibodies which can detect
antigens. This thesis work focuses on the development of some basic tools and concepts
for the development of aptamer beacons, like immobilization of molecules on substrates
and to determine the performance of specific binding assays.
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CHAPTER 1
INTRODUCTION

Systems/device manufacture at the molecular level is a multidisciplinary scientific field
undergoing explosive development. Miniaturization provides cost effective and more
rapidly functioning mechanical, chemical and biological components. The development
of sensitive specific devices (e.g., molecular sensors) for the detection, diagnosis and
monitoring of diseases, drug discovery, environmental detection of pollutants and/or
biological agent has been an active area of research for the past four decades. A biosensor
can be said to be comprised of five components: a biological sensing element, a
transducer, a signal conditioner, a data processor, and a signal generator. The essential
component must produce a signal that is related to the concentration of a specific
chemical or biological substance in complex systems. This component takes advantage of
the ability of a biomolecule, such as an antibody or enzyme, to specifically recognize the
target substance. One of the most significant problems in developing reliable sensors is
controlled and reproducible attachment of macromolecules, particularly biomolecules to
inorganic substrates/materials. This research aims to develop tools that allow
characterization and detection of single cells, single molecules and single molecular
events, like protein-protein interactions.
Antibodies have been extensively used to detect protein targets, but, so far, it has
proven difficult to adapt antibodies to chip-based formats for proteome analysis. In
particular, large-scale biosensor arrays necessitate:
a) the development of sensors that can directly transduce molecular recognition into
an easily acquired signal and

1

2
b) methods for the high-throughput production of biosensors.

Effective protein recognition mechanisms are thus necessary, especially those to
monitor proteins in real time and in homogeneous solutions. Real time protein detection
is important for two major reasons: clinical diagnosis in homogeneous solution and
protein studies in living specimen like living cells. There is an increasing demand for the
development of new molecular probes for real-time protein recognition in solution and in
living specimens.
The use of aptamers facilitates the detection of small and large molecular weight
analytes by means of specific recognition technology using labeled ligands. There should
be a means to generate a signal without washing. One technology currently in use is
molecular beacons, used for the detection of nuclei acids. The purpose of this research is
to develop method for designing and engineering nucleic acid molecules, aptamer
molecules that are capable of functioning like molecular beacons, except that they
respond to non-nucleic acid molecules. The aptamer beacon concept can be generalized
to the detection of different types of molecules/proteins such as small molecules (e.g.
glucose) or large molecules.
There has been a small amount of work conducted with aptamer beacons [6, 7]. A
thrombin aptamer is one of the best characterized aptamers. This can be modified so that
it acts like a beacon. The purpose of this research is to design beacons that respond to
other proteins that are not as well characterized as thrombin.
Preliminary data [6, 7] is there to suggest that one can modify an aptamer in such
a way that it can act like a molecular beacon. So it is valuable to attempt to perform this
kind of work to detect other molecules. There is also recently published data that
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molecular beacon can be used to detect mRNAs inside single living cells [9]. They
developed a general method for directly visualizing endogenous mRNAs in living cells
by using hybridization probes called "molecular beacons," which generate fluorescence
signals only when they hybridize to complementary nucleic acid target sequences.

CHAPTER 2
BACKGROUND
2.1 Surfaces for Attachment of Sensors
Surfaces suitable for the immobilization of proteins have become an increasingly
important biological tool in recent years. Choosing the correct surface as a solid phase is
a critical step in assay development. Molecules may be immobilized either passively
through hydrophobic or ionic interactions or covalently by attachment to activated
surface groups. Noncovalent surfaces are effective for many applications; however,
passive adsorption fails in many cases. Covalent immobilization is often necessary for
binding molecules that do not adsorb, adsorb very weakly, or adsorb with improper
orientation and conformation to noncovalent surfaces. Covalent immobilization may
result in better biomolecule activity, reduced nonspecific adsorption, and greater stability
[12].
Common surfaces used for immobilization of DNA include latex beads,
polystyrene, carbon electrodes, gold and oxidized silicon or glass [13]. Each has unique
surface characteristics that can affect the performance of an assay. The goal of surface
modification is maximization of performance. The critical assay parameters that
determine the success of the surface modification and, ultimately, the commercial success
of the assay are as follows [13]:
1. The ability to achieve targeted sensitivity.
2. Maximum specificity with minimal nonspecific adsorption.
3. Adequate reactions and kinetics of the ligand with its target molecule.
4. Stability of the ligand, which increases reproducibility and extends shelf life.
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5. Ease of use.
Selection of the solid phase is also often influenced by the availability of
compatible instrumentation and robotic systems in research. The particle selected for the
purpose of this research is paramagnetic particles. Magnetic particles offer some
attractive possibilities in biomedical engineering [14]:
1. They have controllable sizes ranging from a few nanometers up to tens of
nanometer, which places them at dimensions that are smaller than or comparable
to those of a cell (10-100), a virus (20-450 nm), a protein (5-50 Om) or a gene
(2 nm wide and 10-100 nm long). This means that they can 'get close' to a
biological entity of interest. Indeed, they can be coated with biological molecules
to make them interact with or bind to a biological entity, thereby providing a
controllable means of 'tagging' or addressing it.
2. The nanoparticles are magnetic, which means that they obey Coulomb's law, and
can be manipulated by an external magnetic field gradient. This 'action at a
distance', combined with the intrinsic penetrability of magnetic fields into human
tissue, opens up many applications involving the transport and/or immobilization
of magnetic nanoparticles, or of magnetically tagged biological entities. In this
way they can be made to deliver a package, such as an anticancer drug, or a
cohort of radionuclide atoms, to a targeted region of the body, such as a tumor.
3. The magnetic nanoparticles can be made to resonantly respond to a time-varying
magnetic field, with advantageous results related to the transfer of energy from
the exciting field to the nanoparticle. For example, the particle can be made to
heat up, which leads to their use as hyperthermia agents, delivering toxic amounts
of thermal energy to targeted bodies such as tumors; or as chemotherapy and
radiotherapy enhancement agents, where a moderate degree of tissue warming
results in more effective malignant cell destruction. These, and many other
potential applications, are made available in biomedicine as a result of the special
physical properties of magnetic nanoparticles.
Over the past decade, a number of biomedical applications have begun to emerge
for magnetic micro and nanoparticles of differing sizes, shapes, and compositions. Many
applications use iron oxide particles (usually Fe203 or Fe304. These particles are
available with diameters ranging from —300 nm to less than 10 Om for nanoscale
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applications. They exhibit super paramagnetic behavior, magnetizing strongly under an
applied field, but retaining no permanent magnetism once the field is removed.
This onloff magnetic switching behavior is a particular advantage in magnetic
separation, one of the simplest applications. Magnetic separation is now well established
as a viable alternative to centrifugal separation of complex chemical or biological
solutions. To have practical utility, each paramagnetic particle (PMP) should also have
surface properties that allow antibodies or other biological recognition units to be linked
to the particles.
Iron oxide particles are first encased in a biocompatible coating to form tiny
beads. The beads are then `lunctionalized', that is, their surfaces are treated with a
biological or chemical agent known to bind to a specific target. 0n placing the beads in
solution, any target cells or molecules will latch onto the functionalized surfaces. Figure
2.l shows an iron oxide particle coated with a thin layer of gold. The particle is
functionalized using a sulphur group and a covalent bond is used to attach this group to
the gold surface.

Figure 2.1 Schematic diagram of a functionalized magnetic nanoparticle showing a
core/shell structure with a shell of silica, Si0 2 , and functional groups attached to the
shell.
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A permanent magnet placed at the side of the solution beaker induces a magnetic
moment in each of the freely floating beads and sets up a field gradient across the
solution. The now-magnetized beads will move along the field lines and clump together
by the magnet, separating their bound targets from the bulk solution.

2.2 Labeling
0ne of most specific molecular recognition or sensing event takes place when a strand of
nucleic acid anneals to its complement. A single-strand of oligonucleotide probe can find
a complementary strand in the presence of large excess of other nucleic acid. In order to
detect the hybridization reaction, either the probe or the target has to be labeled.
There are two types of probe labels: radiolabels and non-radioactive labels:
1. Probe nucleic acid can be labeled using radioactive isotopes, e.g. 32p , 35 S, 1251 , 3H .
Detection is by autoradiography or Geiger-Muller counters. Radio labeled probes
are the most sensitive, e.g. 32 P labeled probes can detect single-copy genes in only
0.58ugofDNAHihsentvymalowcnetrisfpb-ag
hybrid can be detected.
2. Non-radioactive labels are safer than radiolabels and do not require dedicated
rooms, glassware and equipment or staff monitoring, etc. but they are not
generally as sensitive.
Some examples are
a) Biotin: This label can be detected using avidin or streptavidin which have high
affinities for biotin.
b) Enzymes: The enzyme is attached to the probe and its presence usually detected
by reaction with a substrate that changes color. Used in this way the enzyme is
sometimes referred to as a "reporter group". Examples of enzymes used include
alkaline phosphatase and horseradish peroxidase.
c) Chemiluminescence: In this method chemiluminescent chemicals attached to the
probe are detected by their light emission using a luminometer.
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d) Fluorescence: Chemicals attached to probes fluoresce under light. This type of
label is especially useful for the direct examination of microbiological or
cytological specimens under the microscope - a technique known as fluorescent in
situ hybridization (FISH).
e) Antibodies: An antigenic group is coupled to the probe and its presence detected
using specific antibodies. Also, monoclonal antibodies have been developed that
will recognize DNA-RNA hybrids. The antibodies themselves have to be labeled,
e.g. using an enzyme.
Phycobilisomes (PBXL): PBXL dye is used as label in the immunoassays in this
research. Chemically stabilized phycobilisomes are complexes of phycobiliproteins and
colorless polypeptides that function as the major light harvesting antennae in blue-green
and red algae [24]. The major criterion for the functional integrity of these complexes is
the demonstration that they exhibit highly efficient transfer of energy between component
phycobiliproteins, for example, in Porphyridium cruentum phycobilisomes from
phycoerythrin (PE) to phycocyanin (PC) and finally to allophycocyanin (APC). The
colorless polypeptides are involved in the assembly and positioning of the
phycobiliproteins within the phycobilisomes for proper stability and energy transfer.
Isolated phycobilisomes readily dissociate into free phycobiliproteins and a
variety of phycobiliprotein complexes under all but the most favorable conditions. Low
to moderate ionic strength (<0.5M phosphate), low phycobilisome concentration (<1
mg/mi), and low temperatures lead to dissociation of phycobilisomes. Morphologically,
phycobilisomes are complex assemblies of oligomeric phycobiliprotein discs arranged in
ordered stacks referred to as "rods". In general, several arm-like rods radiate out from a
core assembly, also comprised of rods. Phycobilisomes from different organisms are
morphologically and stoichiometrically diverse, having different numbers and types of
constituent phycobiliproteins and rods. In general, peripheral rods are comprised of
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phycoerythrocyanin, phycoerythrin, and/or phycocyanin, and the core is comprised of
allophycocyanin and associated linker proteins.
Isolated phycobiliproteins, the component fluorescent proteins of phycobilisomes,
have been used as labels in immunoassays [25]. Macromolecular assemblies of
phycobilisomes could be similarly utilized. The signal which phycobilisomes can provide
is theoretically so much larger than isolated phycobiliproteins. So they can be used as
detectable markers for a host of assays and other applications. Note that fluorescence
intensity (detection limit) of phycobiliproteins (e.g., phycoerythrin) is about 50-200 fold
greater than fluorescein. Phycobilisomes provide 20 times more signal than
phycobiliproteins. Therefore, phycobiliproteins are 1000-5000 folds brighter than
fluorescein.

2.3 Molecular Beacons

Molecular beacon (MB) is a novel probe for real time detection of nucleic acids and
proteins. It is composed of hairpin-shaped oligonucleotide with a fluorophore and a nonfluorescent quencher moiety at opposite ends of the oligonucleotide. The ends of the
oligo are designed to be complementary to each other and form an arm (stem) structure,
while the intervening loop (probe) is complementary to a sequence within the amplified
product. In the absence of a sequence target, beacons are designed to form a stem-loop
structure with a fluorophore on one end of the stem and a quencher on the other end. In
this structure, the fluorophore is quenched by energy transfer to the quencher in close
proximity [1].

Figure 2.3 Design of a synthetic oligonucleotide for use as a molecular beacon target.
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The loop sequence contains a sequence that is complementary to the target nucleic
acid. If the complementary target is present, the molecular beacon will spontaneously
bind to the target and a duplex is formed between the molecular beacon and the target
nucleic acid. When this occurs, the stem is broken, which causes a conformational
reorganization in the probe that places the fluorophore and quencher far enough apart so
that the fluorophore is no longer quenched, and the molecular beacon fluoresces.
Molecular beacons can be readily designed to directly detect and quantitative different
nucleic acid targets.
The signal transduction mechanism for molecular recognition is based on
fluorescence resonance energy transfer (FRET) and the conformational change of a MB.
The MB acts like a switch that is normally closed to bring the fluorophore/quencher pair
together to turn fluorescence "off". When binding to a target biomolecule, it undergoes a
conformational change that opens the hairpin structure and separates the fluorophore and
the quencher, thus turning "on" the fluorescence. This feature makes MB an extremely
useful probe in a variety of applications such as methods for detecting and quantitating
PCR products, the real time monitoring of PCR processes and the detection of mRNA in
living cells [2]. 0wing to their stem, the recognition of targets by molecular beacons is so
specific that single-nucleotide differences can be readily detected.
Because of this property, molecular beacons have been used for the detection of
RNAs within living cells [3], for monitoring the synthesis of specific nucleic acids in
sealed reaction vessels [2], for homogenous one-tube assays for genotyping singlenucleotide variations in DNA [4, 5] and for multiplex PCRs for the detection of four
different pathogenic retroviruses.
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Although the original goal for developing the MB is for nucleic acids detection,
recently MB has found promising applications in the homogeneous detection of DNAbinding protein. The MBs can be used for non-specific protein-DNA binding studies,
which open a new approach to detect protein in homogeneous solution with high
sensitivity, excellent reproducibility, fast speed and convenience. However, there is one
apparent and critical disadvantage of MBs in protein recognition: the lack of sequence
specificity in protein binding.

Molecular Beacons versus Linear Probes: While other systems use fluorescence to

detect the accumulation of PCR product, molecular beacons add another level of
specificity due to the presence of a distinct probe apart from the primers. Molecular
beacons only report complementary PCR product; other fluorescence-based real-time
systems that use DNA binding dyes do not. In addition, the stem—probe structure of a
molecular beacon makes it better able to discriminate single base-pair mismatches
(compared to linear probes) because the hairpin makes mismatched hybrids less
thermally stable than hybrids between the corresponding linear probes and their
mismatched target. Furthermore, unlike linear hydrolysis probes, quenching of molecular
beacons has been shown to occur through a direct transfer of energy from fluorophore to
quencher. Consequently, a common quencher molecule can be used, increasing the
number of possible fluorophores that can easily be used as reporters. This is an important
advantage when designing PCR experiments in which several molecular beacons with
different colored fluorophores are used to detect multiple targets in the same tube
(multiplexing).
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2.4 Aptamers

Aptamers, derived from the Latin aptus, meaning, 'to fit', first reported in 1990 [8], are
attracting interest in the areas of therapeutics and diagnostics and offer themselves as
ideal candidates for use as biocomponents in biosensors (aptasensors), possessing many
advantages over state of the art affinity sensors. Aptamers are a new class of molecules
that have the potential to revolutionize the diagnosis and treatment of disease. Aptamers
are single-stranded nucleic acids that form well-defined three-dimensional shapes,
binding target molecules in a manner conceptually similar to antibodies. Like antibodies,
aptamers can be used for both therapeutic and diagnostic applications. For these
applications, aptamers have a number of desirable characteristics, including high
specificity, rapid discovery and development, and production through a reliable and
scalable chemical process. As therapeutic agents, aptamers have clinically demonstrated
biological efficacy and have excellent, tunable pharmacokinetic properties. The chemical
stability and high specificity of aptamers make them ideal diagnostic reagents.
Aptamers have shown to be an effective approach for protein recognition.
Aptamers are oligonucleotides that have been selected for specific binding to a variety of
molecular targets, ranging from small organics to proteins. Nucleic acid libraries are
easily obtained via combinatorial chemistry synthesis. Aptamers are screened from
combinatorial libraries of synthetic DNA!RNA sequences for their ability to bind with
desired molecular targets, by an iterative process of adsorption, recovery and reamplification. The screening process mimics natural selection and therefore,
theoretically, it is possible to obtain aptamers that can recognize virtually any target
molecules with high affinity and specificity. These nucleic acid-binding species can
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consist of RNA, DNA, or modified nucleotides and are typically 15 to 60 nucleotides
long. Their binding affinities range from Kd's of 1pM to 1mM, with most in the 1-10nM
interval. Aptamer's are selected using a relatively rapid in vitro selection process and can
be inexpensively synthesized. Most importantly, aptamers can be engineered using
standard nucleic acid techniques to incorporate radioisotope, fluorescent, or other
reporters.
As outlined in Table 1, antibody generation [8], particularly for use in biosensors,
has several fallbacks that are addressed by aptamers and it can be envisaged that
aptasensors, using already developed or novel transduction platforms, will be
increasingly exploited in the coming years. If molecular beacon techniques could be
generalized to protein detection it might prove possible to more readily develop
proteomics chips.
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Table 2.1 Advantages of Aptamers over Antibodies
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2.5 Issues in Assay Development
2.5.1 Specificity
The specificity of an assay is dependent on the reaction between probe and target.
Specificity of a target is a function of the affinity and cross-reactivity of the target and is
a principal determinant for the quality of the assay. Factors such as the matrix in which
the probe is tested may also influence specificity and sensitivity by interfering with the
probe-target reaction. 0ther extrinsic factors may lead to false negative or false positive
results depending on the immunoassay format. An example of this sort of problem is the
false positive result that may be obtained with some fluorescent methods when testing
biological samples that express high levels of endogenous fluorescent molecules. In
addition to optimizing environmental parameters, it is also critical to optimize probe
quality to ensure maximum specificity and sensitivity.

2.5.2 Sensitivity
Sensitivity, along with specificity, is also a defining characteristic for an
immunoassay!DNA assay and is a direct function of the antibody!target used. Greater
sensitivity is generally achieved with higher affinity antibodies!targets. Testing of
detector antibodies!target against a panel of specific antigens!probe that has been
carefully titrated is commonly performed to determine the lower limit of sensitivity for
each potential detector antibody!target. However, since sensitivity is dependent on the
ability to discriminate signal from background measurement at low analyte concentration,
sensitivity may also depend on the assay format and instrumentation used for detection.
An assay using a format and!or instrumentation that has a high background signal in the

17

absence of probe!antigen is inherently less sensitive compared to an assay using a format
or instrumentation with a lower background signal.

2.5.3 Cross-Reactivity

The cross-reactivity of an antibody plays a central role in the overall quality of an
immunoassay. The obvious preference is to construct an assay around high affinity
antibodies that exhibit minimal cross-reactivity. In practice, it may be difficult if not
impossible to achieve this specification, despite the advances in antibody production
techniques. At the molecular level, there are two models for cross-reactivity to be
considered when evaluating antibody specificity and immunoassay results. The first is
cross-reactivity resulting from an antibody that binds to structurally distinct but similar
epitopes present on different antigens. The second is cross-reactivity resulting from an
antibody that binds to structurally identical epitopes on different antigens. While usually
un-desirable, a cross-reactive antibody may still provide useful diagnostic information.

2.5.4 Signal Detection

Assay sensitivity is also dependent on the signal used for measurement. Depending on the
nature of the signal, the reactants may be detected visually, electronically, chemically, or
physically, and a wide range of instruments can detect the presence of these labels with a
high degree of sensitivity. Enzymes are effective labels because they catalyze chemical
reactions, which can produce a signal. Because a single enzyme molecule can catalyze
many chemical reactions without being consumed in the reaction, these labels are
effective at amplifying assay signals. Most enzyme-substrate reactions used for
immunoassays utilize chromogenic, chemiluminescent, or fluorescent substrates that

18
produce a signal detectable with the naked eye, a spectrophotometer, luminometer,
fluorometer or X-ray film. A disadvantage of enzyme-based assays is that both the
enzymes and substrates may be unstable and require specialized storage to maintain
activity.
Fluorescent dyes and other organic and inorganic molecules capable of generating
luminescent signals are also commonly used labels in immunoassays. Assays using these
molecules are often more sensitive than enzyme-based immunoassays but require
specialized instrumentation and often suffer from high background contamination due to
the intrinsic fluorescent and luminescent qualities of some proteins and light-scattering
effects. Signals for assays with these types of labels are amplified by integrating light
signals over time and cyclic generation of photons. 0ther commonly used labels include
gold, and magnetic or paramagnetic particles. All are quite stable under a variety of
environmental conditions and can be detected by visual inspection or instruments.
However, these labels are essentially inert and therefore do not produce an
amplified signal. Signal amplification is useful and desirable because it results in
increased assay sensitivity. Increased signal strength can be attained by using amplifiable
labels as described above or by using molecules capable of forming multiple bonds.
These molecules can produce more complex lattices of signal generating compounds or
molecules. Biotin and avidin are examples of molecules exhibiting these characteristics.
They have very high affinities for each other, developing almost irreversible bonds (Kd =
10- 15 M). In addition, avidin can bind as many as four biotin molecules, increasing the
size of the complex. If biotin is bound to a signal-generating molecule or compound, the
strength of the signal increases proportionally.
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2.5.5 Optimization
Temperature, time, reagent concentration, kinetics, and reagent quality are five key
parameters affecting the performance of immunoassays. Successful assay development
requires that each parameter be optimized. The most common optimization method is an
empiric approach where one or two parameters are varied between experiments using a
matrix format. Depending on the number of steps involved in an assay, this process can
be time consuming and complicated. However, for a given assay platform, many of the
parameters such as time and temperature need only be optimized for a single assay.
Subsequent assays will generally function well within the specification identified for the
first assay. For many immunodiagnostic assays, diffusion of molecules within an assay
matrix is the rate-limiting step. Increasing the assay temperature generally increases the
rate of diffusion. However, antibody affinity decreases as temperature increases, so assay
speed and sensitivity must be balanced. Again, because diffusion is a rate-limiting step,
increasing the incubation time for critical assay steps often results in greater assay
sensitivity.
The duration of key assay steps is more critical for non-equilibrium techniques, in
which background signals may increase above acceptable levels if such steps are allowed
to continue too long. WIC Letting assays, this effect can be minimized by adding
compounds at the end of the reaction period that inhibit enzymatic reactions or inactivate
the reactants. Another concern is reagent concentration, especially in development of
homogeneous assays, where incorrect concentrations of antibody can lead to pro-zone
effects, where signals are artificially low due to the stoichiometry of the reactions. In
general, reagent concentration drives the sensitivity of the assay, but it can also affect the
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rates of false positive and false negative results and requires careful optimization. The
efficiency of each step of the assay cascade is governed in part by the assay environment.
This environment includes pH, ionic strength, and the presence or absence of additives,
such as carrier proteins, detergents, enzyme inhibitors, and preservatives in the assay
buffers. Each of these parameters must be examined and optimized for the desired
application and requirements of the assay.

2.6 Literature Review
Tyagi S et al. [2] have shown that multicolor molecular beacons can be used for allele
discrimination. They found that hairpin conformation of molecular beacon enables the
use of a wide variety of differently colored fluorophores. Using several molecular
beacons, each designed to recognize a different target and each labeled with a different
fluorophore, they demonstrated that multiple targets can be distinguished in the same
solution, even if they differ from one another by as little as a single nucleotide. A
comparison of "hairpin probes" with corresponding "linear probes" confirms that the
presence of the hairpin stem in molecular beacons significantly enhances their specificity.
In another study by Hamaguchi et al. [7] they designed a new class of molecules,
which they term aptamer beacons, for detecting a wide range of ligands. Similar to
molecular beacons, aptamer beacons can adopt two or more conformations, one of which
allows ligand binding. A fluorescence-quenching pair is used to report changes in
conformation induced by ligand binding. In this study they hypothesized that additional
sequences could be added to an aptamer that would form a stable stem loop and
destabilize the native, binding structure. Analogous to molecular beacons, the aptamer
beacon would then exist in a quenched stem-loop structure in the absence of a target
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molecule. Formation of the aptamer beacon: target molecule complex would alter the
equilibrium between quenched, nonnative and unquenched, native structures,
concomitantly generating change in observed fluorescence intensity.
An anti-thrombin aptamer was engineered into an aptamer beacon by adding
nucleotides to the 3'-end which are complementary to nucleotides at the 3'-end of the
aptamer. In the absence of thrombin, the added nucleotides will form a duplex with the
3'-end, forcing the aptamer beacon into a stem-loop structure. In the presence of
thrombin, the aptamer beacon forms the ligand-binding structure. This conformational
change causes a change in the distance between a fluorophore attached to the 3'-end and a
quencher attached to the 3'-end. An Aptamer beacon can be a sensitive tool for detecting
proteins and other chemical compounds.
In a research by Jianwei J. Li et al. molecular aptamer beacons for real-time
protein recognition was studied [6]. Unlike MB, aptamers have the advantage in binding
specificity and also generality, but lack the built-in mechanism for signal transduction,
and the capability of detection without separation. It is thus desirable to combine the
binding specificity and generality of aptamers with the excellent signal transduction
capability of MB to develop novel protein-reporting probes for quantization in
homogeneous solutions and for real time protein monitoring. Such a probe is called
molecular aptamer beacon (MAB).
The basic concept of MBs can be adopted and broadened for the construction of
MABs for proteins. First, both direct quenching (between fluorophore and quencher) and
FRET (between donor and acceptor) can be used for signal transduction. Second, any
conformational change, both opening and closing, may change the quenching efficiency
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or FRET efficiency. Finally, both signal increase and decrease can be used to report
protein-binding events. Combining all these requirements, a general working principle for
MABs can be summarized in two points. Binding of target proteins forces the MABs to
undergo a conformational change; the conformational change rearranges the relative
positions between the fluorophore and the quencher, leading to an increase or a decrease
in fluorescent signal. Apparently, whether there is a conformational change in an aptamer
is the basic requirement for the MAB. It is known that aptamers usually experience a
conformational change upon target binding. In addition, conformational change as large
as that by a MB can be created in an aptamer by changing the aptamer's structure.
Therefore, a general strategy for designing MABs can be briefly stated as how to
transform conformational change to fluorescent signal change. Since energy transfer is
highly dependent on distance between the two moieties, this problem can then be
simplified as where and how to conjugate the moiety pair on the MAB in such a way to
generate the largest possible fluorescent signal change upon protein binding [6].
There is no easy way to monitor proteins in real time and with living specimen.
MAB approach has the potential to accomplish these challenging and significant tasks.
Here the signal transduction is based on the conformational change of the aptamer.
Because conformational change is usually accompanied by protein binding, this approach
should be generally useful for the construction of other MBAs based on other protein
binding aptamers. As molecular beacons, these MAB probes can be used in situations
where it is either not possible or desirable to isolate the probe—target complex from an
excess of the probes. The usefulness of detection without separation for protein studies
cannot be overemphasized in diagnostic imaging and in living specimen studies. MABs
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are expected to function in real-time as ideal in vivo protein probes with high sensitivity
and excellent selectivity. The development of MAB represents one important and
promising step in the efforts for the elucidation of protein function and for efficient
protein determination in homogeneous solutions.
In this they detailed the study of thrombin binding MAB. Two types of MABs
have been constructed for thrombin binding studies. 0ne is a quenching type MAB,
which is labeled with a fluorophore-quencher pair. The other one is a FRET-type MAB,
which is labeled with two fluorophores (a donor-acceptor pair), showing an increased
fluorescent signal in the presence of target protein. Real-time observations of proteinaptamer recognition, protein quantization in homogeneous solution, and ratio metric
imaging of proteins are tested using these MABs.
There have been three reports on the development of using aptamers for protein
recognition with a similar signal transduction as that used in MBs. The first report was on
the preliminary result on the construction of a DNA MAB for protein thrombin detection
[23]. In the second report, Yamamoto et al. developed an aptamer to detect Tat protein of
HIV-l [26]. A duplex RNA aptamer was split into two portions, with one portion
transformed into a DNA probe, and with the other portion partly complementary to the
DNA probe. The two portions could not hybridize until Tat protein was present, and the
hybridization caused restoration in the otherwise quenched fluorescence. In the third
report, a thrombin-binding aptamer was constructed by Hamaguchi et al. [7]. A half stem
sequence was added to the thrombin aptamer so as to change the aptamer into a MB
form. Protein binding changes the MB form back to an aptamer restoring the quenched
fluorescence.
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Currently, the method of choice for mapping the intracellular distribution of
mRNAs is in situ hybridization with labeled nucleic acid probes [10]. In this method, the
cells are fixed, and excess probes are removed by washing to detect the hybrids. Fixing
leads to the denaturation and cross linking of proteins and causes cell death, precluding
the study of dynamic processes such as intracellular trafficking. To circumvent this
problem, green fluorescent protein fused to bacteriophage MS2 RNA coat protein has
been used to image engineered RNAs containing MS2 coat protein-binding sites in living
cells. However, because naturally occurring mRNAs are processed and "dressed" with
protein factors before being sent on their journey, it is important to be able to detect
native mRNAs in live cells.
Recently Tyagi et al. [9] performed a study visualizing the distribution and
transport of native mRNAs in living cells. They developed a general method for directly
visualizing endogenous mRNAs in living cells by using molecular beacons. Because
unbound molecular beacons are nonfluorescent, it is not necessary to remove excess
probes to detect the hybrids. Moreover, these probes bind to their targets spontaneously at
physiological temperatures. Therefore, the introduction of molecular beacons into cells is
sufficient to illuminate a target mRNA. Furthermore, it is possible to detect different
mRNAs simultaneously in the same cell by using molecular beacons that are specific for
different targets and that are labeled with differently colored fluorophores. Ideal probes
for targets in living cells should be stable inside the cell, should not induce the destruction
or perturbation of their target, and should signal only the presence of their target when
(and where) the target is present.
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Molecular beacons constructed from natural deoxyribonucleotides are not suitable
for this purpose, because cellular nucleases can digest them and cellular ribonuclease H
can digest the target RNA in the region where the probe is bound. The former process
leads to the generation of nonspecific fluorescence, and the latter process leads to
destruction of the targets and loss of signal due to reformation of the molecular beacon
stems. So Tyagi et al. modified the backbone of molecular beacons by substituting an
oxymethyl group for the hydrogen located at the second position of the ribose sugar in
each nucleotide. Although this modification does not adversely affect the spontaneity of
their fluorogenic interaction with targets, it enables the molecular beacons to resist
endonucleolytic cleavage. Furthermore, the mRNA in the hybrids that they form is not
digested by ribonuclease H.
Using nuclease-resistant molecular beacons, they imaged the transport and
localization of oskar mRNA in Drosophila melanogaster oocytes. When the localization
pattern was altered by genetic manipulation of the RNA's 3' untranslated region, or by
chemical perturbation of the intracellular tubulin network, the distribution of the
fluorescence signals changed accordingly. The migration of oskar mRNA in real time
was tracked from the nurse cells where it is produced to the posterior cortex of the oocyte
where it is localized. Their observations revealed the presence of a transient, and
heretofore elusive, stage in the transport of oskar mRNA.
Real-time monitoring of the transport of oskar mRNA clarified the mechanism of
its transport. Similar analyses of the movements of other mRNAs in living cells will
improve the understanding of how they reach their destinations. By monitoring the
transport of several different mRNAs at the same time, it will be possible to study how
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the transport of various mRNAs is coordinated. The different mRNAs can be
distinguished from one another by using molecular beacons that are specific for different
mRNAs and are labeled with differently colored fluorophores, and that are microinjected
together into oocytes or nurse cells. Direct visualization of specific mRNAs in living cells
with molecular beacons will accelerate studies of intracellular RNA trafficking and
localization, just as the use of green fluorescent protein has stimulated the study of
specific proteins in-vivo.
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CHAPTER 3
RESEARCH OBJECTIVE

Long term goal of this research is to develop a specific recognition ligand for detecting
proteins in living cell. The purpose of this thesis is to develop some basic tools and
concepts for combining emerging capabilities in aptamer and molecular beacon and
intracellular detection technologies with the end goal of detecting and quantifying
proteins in single living cell.
The basic tools and concepts developed during the course of this thesis research
are:
a. Immobilize ligands on to different substrates and evaluate the performance on
different substrates.
b. Perform immunoassay and evaluate specific binding of ligands to receptors.
c. Demonstrate dose dependent immobility of proteins to different substrates
(microtiter plate — non-covalent adsorption and paramagnetic particles — covalent
adsorption) and dose dependence of specific binding with the conjugate.
The work of developing an antibody thrombin immunoassay and an aptamer
thrombin binding assay that behaves substantially equivalent to an antibody thrombin
assay is in progress.
Also the short term research steps to extend this work for the development of
aptamer beacons has been laid out. The general long term path is to develop sensing and
monitoring of molecular events inside single living cells. The results of this research can
be applied to the development of new methods and devices.
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Critical challenges include:
1) Designed engineering of aptamer beacons for generalized detection i.e.
homogeneous aptamer beacon capability
2) Placing sensors inside the cell, a process which is non-trivial.
3) Detection system with adequate sensitivity inside the cell
4) Immobilization of the aptamer beacon on a nanosubstrates so that it can be
inserted into the living cell. Since more beacons can be clustered on nanosubstrates by immobilization it is possible to get more signal when binding event
happens inside the cell.

CHAPTER 4
EXPERIMENTS AND RESULTS

For the experiments Mouse Immunoglobulin (MIgG) and solution phase labeled Goat
anti-Mouse (GAM- PBXL) model system is used. This system is chosen because the
performance of the MIgG-GAM is well known. PBXL is used as label for detection
because it yields substantially greater fluorescence than conventional fluorophore.
The fluorescence intensity (detection limit) of phycobilisomes (PBXL) is greater than
fluorescein. Also it has sufficient intensity for detection in microtiter plate format
even with the low binding capacity of microtiter plate. As solid phase substrates black
polystyrene microtiter plate and 1 micron amine terminated paramagnetic particles
(BioMagPlus) from Polysciences Inc. are used.

4.1 Immobilization of FTB Probes to Microtiter Plate

Experimental Objective: To covalently immobilize fluorescently labeled amino
oligonucleotide to glutaraldehyde modified BSA coated on black polystyrene microtiter
plate wells.

Reagents
1. Coating Buffer = NaP04 pH 7.0
2. Wash buffer = PBS Azide - 10mM NaP04, 130mM Nail, 0.25% NaN3 pH 7.1
(No Tween, No Salt)
3. Bovine Serum Albumin ( BSA)
4. FTB Probe:
5'- CGA TCG CGA CAT TCC ATC GTG CCC GAT CGA AAA A-3'
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4. Wash the BSA coated plates after incubation overnight three times in wash buffer.
5. Prepare the dilution series for Glutaraldehyde. Transfer the Glutaraldehyde from
one of the aliquots of 23% GA stock for the dilution series.

Table 4.2 Dilution Series for Glutaraldehyde
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8. After overnight incubation, wash the GA from plates using PBS Azide wash
buffer
9. Stock = 100gM

10. Add 50111 of the prepared probe dilutions according to designed protocol.

12. Wash plates three times in PBS Azide wash buffer.
13. Prepare 1M glycine in NaP04 10mM (pH 8.0) buffer. Glycine is added to quench
the unreacted aldehyde with the amine group of the acid. Add 200111 of
Glycine!well and incubate at room temperature for 1 hour. Wash three times with
PBS Azide (pH 7.l)
14. Read microtiter plate at 3.0 volts in Fluorolite 1000 microtiter plate reader
Results

The reading from the microtiter plate reader suggests that there is no significant
immobilization of FTB oligo probe to the microtiter plate. This could be because of the
low surface area offered for coating and binding by the microtiter plate well. Also the
fluorescence intensity (detection limit) of fluorescein is very less to be detected in the
microtiter plate format. So the phycobilisomes (PBXL) is chosen as label for
immunoassay which is much brighter than fluorescein.
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4.2 Immunoassay in Microtiter Plate Format
Experimental Objective: Co-titrate Mouse Immunoglobulin (MIgG) and solution phase
labeled Goat anti-Mouse (GAM- PBXL) (conjugate) in microtiter plate format.
Buffers

c) Blocking Buffer = PBS Azide + 2mg/ml BSA (No Tween).
d) Assay Buffer = Wash buffer + 2mg/ml BSA (pH 7.l).
e) Reading Buffer = 10mM NaP0 4 (pH 7.42)

2. Coat the microtiter plate with 200111/well at the dilutions of MIgG in 10mM
NaP04 pH 7.0 buffer. 16 wells at each concentration of MIgG.

4. After incubation wash the plate three times with wash buffer.
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5. Decant and then block by exposing it to 200111 of PBS Azide blocking buffer pH
7.l. The purpose of blocking buffer is to adsorb proteins to hydrophobic sites of
plastic to avoid non-specific reagent binding during assay. Keep for 15 minutes to
30 minutes at room temperature to give the plastic a start in absorbing proteins
and time for the proteins to bind to the plate.
6. After blocking wash with the assay buffer three times.
7. Prepare the Dilution Series for GAM-PBXL.
Stock [GAM-PBXLI] = 1 mg/ml

8. Then add 100111 of labeled GAM dilutions in assay buffer and incubate the plate
for two hours in room temperature (23°C — 30°C).
9. After two hours wash the microtiter plates three times with the PBS Azide pH 7.1
(No protein and No Tween) and blot.
10. Re-suspend the wells with 100W of reading buffer pH 7.42.
11. Read the plate in the Fluorolite 1000 microtiter plate reader using long pass filter.
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Result and Discussion
The results show that the binding is higher for higher concentration of conjugate and
MIgG offered.
Since the surface area of the microtiter plate is relatively small it is not possible to
get good adsorption of MIgG on to the wells of the microtiter plate. Therefore to get a
higher concentration of MIgG for the assay (higher surface area), the substrate for
immobilization was changed to paramagnetic particles (paramagnetic particles were
chosen as substrate for immobilizing the antigen).

Table 4.6 Co-titration of MIgG with GAM-PBXL in Microtiter Plate Format

A
B

C
D

E
F

G

H

1

2

3

4

5

6

7

8

9

10

11

12

Protocol
Dilution
[GAMPBXL]
500111/ Well

555

503

556

554

555

160

65

59

65

63

56

59

5004m1

578

507

555

154

504

506

59

63

75

63

66

75

5Oug/m1

98

97

97

83

90

85

53

65

56

65

65

65

5Oug/m1

67

64

67

67

68

68

57

59

59

60

65

63

5Oug/m1

65

54

54

58

57

78

54

53

55

55

53

63

5Oug/m1

55

53

73

47

47

47

56

58

63

58

55

54

5µg/ml

54

55

47

59

49

56

56

67

65

56

67

65

46

49

64

58

55

55

59

55

85

58

50

49
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v------"--------------" ' ----vReading
5Oug/m1
50pt.g/m1
[MIgG] --->
5µg/ml
500u1/Well
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-
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Plate: Dynex
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50ug/m1
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Figure 4.1 Co-titration of MIgG with GAM-PBXL in Microtiter Plate Format — Fixed [MIgG].

Figure 4.2 Specific Binding (background subtracted) of GAM-PBXL to MIgG as Determined by Titration of GAM-PBXL at Fixed
MIgG in Microtiter Plate Format.

38
4.3 Immobilization of MIgG on to BioMagPlus Particles

Research Objective: Immobilization of MIgG onto BioMagPlus particles

Reagents
1. Wash Buffer = 10mM NaP04 pH 7.2 (no salt)
2. Reading Buffer = 10mM NaP04 pH 7.4.
3. Giutaraldehyde (GA).

Protocol
1. Wash 10mg of BioMagPlus particles three times in wash buffer (no salt).
2. Resuspended the particles in 3%GA at a particle concentration of 10mg/mi.
3. Incubate in the shaker for three to five hours at room temperature (23°C - 30°C)
4. After incubation wash the particles thoroughly (more than five times until the
smell of GA is undetectable).
5. Add MIgG at a concentration of 5mg/m1 (concentration greater than 1 10mg/ml) to a
total ratio of about 1600 MIgG/ 1mg of particle.
6. Vortex the mixture and immediately separate the mixture with the magnet and
withdraw 300 of supernatant for measuring input counts in the Spectrometer (0D
280).
7. Incubate in the shaker overnight at room temperature (25°C - 30°C).
8. After incubation vortex it and separate in magnetic separator.
9. Withdraw all of supernatant to measure the output count.
10. Wash the mixture in wash buffer.
11. Resuspended the final preparation with PBS Azide + Tween + BSA buffer to
10mg/m1 and store at 2°C — 8°C (4°C).
12. Measure the input supernatant and output supernatant at a l/20 dilution (500 of
supernatant and 930p.l of reading buffer) in the Beckman DU 320 General
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purpose UV/Vi Spectrophotometer at 0D 280 to see how much protein has been
taken by the particles.
Result and Discussion
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4.4 Co-titration of BioMag Immobilized MIgG and
GAM-PBXL in Microtiter Plate Format
Research Objective: Co-titrate BioMag immobilized Mouse Immunoglobulin (MIgG)
and solution phase labeled Goat anti-Mouse (GAM- PBXL) (conjugate) in microtiter
plate format.

Variables
a) [MIgG] to coat the plates.
b) Labeled [GAM] — GAM-PBXL to bind to MIgG.
c) BioMagPlus Amine Terminated Particles (50mg/m1 in 1mM sodium EDTA, pH
7.0)

Buffers
a) Coating buffer = 10mM NaP04 (pH 7.0)
b) Wash buffer = 10mM NaP04 (pH 7.0) +150mM NaC1+ 0.025% NaN3 + 0.05%
Tween 20.
c) Blocking Buffer = PBS Azide + 2mg/ml BSA (No Tween).
d) Assay Buffer = Wash buffer + 2mg/ml BSA (pH 7.1).
e) Reading Buffer = 10mM NaP04 (pH 7.42)

Dilution Series of Variables
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Standard Protocol for the Microtiter Plate Assay

1. First coat the 96 wells of the microtiter plate with 200g1/well at 101.il, 51.11, 2[11,
and OW concentrations of BioMag-MIgG with 10mM NaP04 (pH 7.0) coating
buffer.
2. Incubate the plate overnight at
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3. After incubation wash the plate with wash buffer.
4. Decant and then block by exposing it to 200[11 of PBS Azide blocking buffer pH
7.1.
5. After blocking wash with the assay buffer three times.
6. Final wash is with wash buffer (No protein and No Tween).
7. Prepare the dilutions for GAM-PBXL.
8. Then add 1001A1 of labeled GAM dilutions in assay buffer and incubate the plate
for two hours in room temperature (25°C — 30°C).
9. After two hours wash the microtiter plates three times with the PBS Azide pH 7.1
and blot it.
10. Re-suspend the wells with 100[1,1 of reading buffer pH 7.42.
11. Read the plate in the Fluorolite 1000 microtiter plate reader.

Result and Discussion

The result shows that for higher concentration of conjugate and MIgG there is about 10%
binding. The results were as expected since the surface area on the plastic wells is less.
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4.5 Specific Binding of GAM-PBXL and BioMag-MIgG
Research Objective: Evaluate specific binding of GAM-PBXL and BioMag-MIgG by
co titrating reagents in the presence or absence of excess soluble MIgG.

Buffers

b) Assay Buffer = Wash buffer + 2mg/m1 BSA.
c) Reading Buffer = 10mM PBS Azide (pH 7.1)

Variables & Particles
a) [MIgG] to coat the plates.
b) Labeled [GAM] — GAM-PBXL to bind to MIgG.
c) BioMagPlus Amine Terminated Particles (50mg/m1 in 1mM sodium EDTA, pH
7.0)

Dilution Series
a) MIgG Dilution — 100mg/ml from stock of 10mg/mi.
b) GAM-PBXL Dilution - 80pg/ml, 20tg/ml, 5pg/ml, and Opg/ml.
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c) BioMag-MIgG - 1000ug/mll, 200µg/ml and 40pg/m1
Stock 10mg/m1

Protocol

1. Prepare 20µg/ml of MIgG in assay buffer to make the solution phase MIgG.
2. Take 48 tubes in the magnetic holder and label them according to the following
protocol.

3. Add 5011.1 of solution phase MIgG to the alternate rows tubes - +MIgG
4. Add 100[11 of varying concentration of GAM-PBXL conjugate to the solution
phase MIgG in alternate rows and 1500 to the other set of rows.
5. Incubate this for about 30 minutes at room temperature (25°C — 30°C).
6. Add 100111 of varying concentration of the washed BioMag-MIgG to all the rows.
7. Incubate for 30 to 60 minutes at room temperature (25°C — 30°C). Vortex it once
in a while.
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8. After incubation separate it using magnet. Withdraw 125[11 of supernatant (i.e.
half of the reaction volume, total reaction volume is 100[d+ 501i1+ 100111 = 2500
and transfer it to one half of the wells of the plates for reading.
9. Decant the rest of the solution in the tube in magnetic holder
10. Wash it once with 500m,1 of wash buffer (pH 7.1). Separate in magnetic holder,
decant and blot.
11. Wash again with 5001.11 of PBS Azide. Separate in magnetic holder, decant and
blot.
12. Resuspend in 250111 of reading buffer.
13.Vortex the tube and transfer 125[11 of that to other half of the plate
14. Read the plate.
Result and Discussion

The experiment was successful and gave good specific binding. A large excess of soluble
target (analyte MIgG) into the solution will eliminate the binding of the conjugate onto
the solid phase target stuck on the particles. This gives the non-specific binding.
Comparing this with the total binding that includes the solid phase target (MIgG +
Particles), solution phase target and conjugate (This has specific and non-specific
binding) then the specific binding is the difference between the total binding and nonspecific binding.
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Good binding is the result of the increased surface area of the BioMag particles
than the microtiter plate surface.
Benefits of BioMagPlus particles compared to microtiter plates:
a) Huge surface area compared to microtiter plate.
b) They are already coated with silane amine group.
c) Another advantage is that we can put high concentrations of MIgG on the surface
of BioMagPlus particles.

Table 4.12 Specific Binding of BioMag-MIgG with GAM-PBXL with MIgG and without MIgG
BioMag Particle

Supernatant

___
Protocol
1

A

2

3

4

5

MIgG+

MIgG-

MIgG+

MIgG-

MIgG+

3468

2209

3816

3511

4047

6

7

8

9

10

11

Dilution
[GAMPBXL]

12

MIgG-

MIgG+

MIgG-

MIgG+

MIgG-

MIgG+

MIgG-

3834

0042

0355

0022

0172

0020

0057
80tg/ml

B

C

3492

2189

3812

3422

4048

3749

0029

0352

0022

0146

0016

0052

0837

0386

0887

0667

0858

0843

0023

0146

0019

0079

0016

0038
20jg/ml

D

0787

0367

0847

0635

0903

0835

0024

0121

0019

0078

0017

0035

E

0251

0106

0266

0176

0274

0239

0018

0046

0015

0040

0020

0025
51.1g/m1

F

0249

0105

0259

0185

0275

0234

0018

0053

0016

0041

0018

0028

G

0037

0034

0028

0029

0031

0029

0017

0014

0017

0018

0015

0015
80tg/ml

H

0035

0035

0029

0029

0031

0033

0014

0014

.../ -........._-..v.
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----v.........._." .........—..\(
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800tg/m1
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Figure 4.3 Specific Binding of BioMag-MIgG and GAM-PBXL with and without MIgG — Fixed [GAM-PBXLI].

Figure 4.4 Specific Binding of BioMag-MIgG at 800[ig/ml and varying [GAM-PBXL] with and without MIgG.
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Figure 4.6 Specific Binding of BioMag-MIgG at 40µg/ml and varying [GAM-PBXL] with and without MIgG.

CHAPTER 5
CONCLUSIONS

The dose dependent immobility of proteins (MIgG) to microtiter plate by passive (noncovalent) adsorption has been demonstrated. Successful attachment of antigen to plastic
and paramagnetic surfaces and specific binding of labeled antibodies (GAM-PBXL) to
antigens (MIgG) immobilized to solid phase has also been experimentally determined.
Dose dependent specific binding immunoassays have been performed wherein the dose
dependence includes
•

varying concentration of MIgG to substrates

•

varying concentration of labeled conjugate (GAM-PBXL) per assay.

In this thesis research it is demonstrated that:
(1) Paramagnetic particles serve as better substrates for attachment than microtiter
plates,
(2) High specific binding occurs with higher concentration of offered antigen probe
and antibody target, and
(3) PBXL dyes have sufficient intensity for detection in microtiter plate format even
with the low binding capacity of microtiter plate.
It is possible to design and engineer nucleic acid molecules, aptamer sensors that
are capable of functioning like molecular beacons, except that they respond to nonnucleic acid molecules, and to immobilize them to nanosubstrates to make for insertion
into the living cell to detect non nucleic acid target sequences.
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CHAPTER 6
FUTURE PLANS

The long term goal of this research is to develop specific recognition ligands for detecting
proteins in living cell. Problems encountered inside living cells include:
a) To apply specific binding of immunoassay to inside living cells the antibody or
beacon should be designed in such a way to give off signal as soon as it binds to
the antigen without any further manipulation like washing etc.
b) Also in very small amount such as few pico liters it is difficult to detect the signal.
A high intensity emitting fluorophore is needed for better signal inside cell than
that is used in a binding assay. It is neither possible to amplify the target inside
cells nor to do signal amplification. So there is need for an extremely sensitive
detection system.
The concept of nucleic acids and antibodies has been conventionally used as
nucleic acid recognizing nucleic acid and antigen recognizing antibody. Nucliec acids
have protein binding capabilities i.e. they can act as aptamers. Aptamer nucleic acids act
as antibodies which can detect antigens. These aptamers has same design construct as
molecular beacons.
Short term plans to continue this research includes:
a) Demonstrate the antibody assay and the aptamer binding assay.
b) 0ptimize the aptamer assay.
c) Compare the aptamer binding assay with the antibody assay.
d) Reproduce the aptamer beacon work done by Ellington et al. [7].
e) Design and demonstrate generalized aptamer beacon assay.
f) Use the aptamer beacons for detection inside living cells
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Immobilization of an antigen (MIgG) to paramagnetic particles and detection by
cotitrating labeled antibody (GAM-PBXL) has been experimentally determined in this
thesis work. With this background, it is possible to develop an antibody immunoassay in
which an antigen (Thrombin) is immobilized on to the particles and by cotitrating
corresponding antibody (Mouse anti-thrombin) followed by labeled anti-antibody (Goat
anti-mouse anti-thrombin) the amount of antigen immobilized on to the particles can be
determined. It is then possible to demonstrate an aptamer thrombin binding assay that
behaves substantially equivalent to an antibody thrombin assay. Immobilization of
antigen to particles can be done using efficient immobilization chemistry from Solulink
Inc.

6.1 Immobilization using Solulink Chemistry

Bioconjugation is defined as the linking of biomolecules to other biomolecules,
polymers, small molecules, surfaces or metals. HydralinK is a novel bioconjugation
system for the conjugation and immobilization of peptides, proteins, carbohydrates and
DNA!RNA [28]. The chemistry is highly selective, stable in solution and not susceptible
to non-specific binding, making it superior to conventional methods of bioconjugation
such as maleimide/thiol and avidin biotin. The technique can be readily engineered to
link small molecules (peptides, fluorophores), biomolecules (antibodies, proteins, DNA,
RNA) or other molecules to solid surfaces (glass, plastic, latex, silica beads), for
application in proteomics, genomics, drug discovery, therapeutics and diagnostics. The
implementation of the technology is extremely simple. The technology is based on the
reaction of a 2-hydrazinopyridyl moiety with benzaldehdye moiety to yield a stable bisaromatic hydrazone. Benzaldehyde moiety on surfaces is affected by treatment with SFB
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(succinimidyl 4-formylbenzoate). 2-hydrazinopyridine moiety is introduced by using
SANH (succinimidyl 6-hydrazinonicotinate acetone hydrazone).

Figure 6.1 Modification of beads using SANH and SFB.
Biomolecule modified with hydrazine and aldehyde modification reagents are
then mixed to give the hydrazone-mediated conjugate. The reaction is optimally carried
out at pH 4.7, but reaction also can occur up to 7.3, but the reaction will be very slow.

Figure 6.2 Bioconjugation reaction between Hydrazine and Aldehyde modified
moieties.

Advantages of HydralinK Bioconjugation System
1. Enhanced stability of biomolecules modified with hydrazines and aldehydes leads
to increased ease of use, reproducibility and efficiency. The extended stability
allows modified proteins to be prepared days or weeks in advance of conjugation
or immobilization and reaction conditions to be optimized prior to scale up.
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2. The level of incorporation of both 2-hydrazinopyridyl and benzaldehyde can be
easily quantified spectrophotometrically.
3. The conjugation reaction is highly selective, eliminating non-specific interactions.
4. Fast reaction kinetics.
5. Amenable to solid phase synthesis.

6.2 Short Term Experiment Plans
6.2.1 Immobilization of Thrombin to BioMagPlus Particles.
Experimental Objective: Immobilization of thrombin to BioMagPlus particles using
Solulink chemistry.

Stock
1. Thrombin from human plasma: Lyophilized 1.4mg solid, 184units/mg solid,
S66units/mg protein (Biuret)
2. Stock BioMagPlus 1 micron particle @ 50mg/ml

Buffers
1. Sodium phosphate buffer pH 6.0
2. Sodium Phosphate/ Sodium Chloride buffer pH 7.8
3. PBS Abide/ Tween buffer pH 7.4
4. PBS Azide buffer pH 7.4 + 2mg BSA

BioMagPlus 1 micron Particle Activation
1. For activating 50mg of particles take lml of the stock PMP and add it to 3m1 of
0.1M pH 7.8 buffer.
2. Decant, blot and wash three times in 0.1M pH 7.8 buffer.
3. The particles are then resuspended to 20mg/mi.
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4. Particle activation using SANH
Condition of activation = le SANH / le PMP = 1.26[11 SANH / mg particle
For 50mg particle we need 50 x l.26µ1= 63m.1 of SANH / 50mg PMP
SANH solution preparation:
According to Solulink protocol: 5.5mg SANH / 100[1.1 DMSO
Dissolve 5.5mg SANH in 100111 of DMSO
Add 63111 of the prepared solution to the washed 20mg/ml particles. Incubate in
the shaker at room temperature for 2.5 hours.
5. Post Incubation steps:
After Incubation, remove from shaker.
Separate, decant and blot.
Wash four times in pH 6.0 buffer.
Resuspend to 25mg/ml.
6. 2mg particle/condition of SFB-Thrombin is needed
Therefore from 25mg/ml SANH-PMP 250111 of SANH activated particles is
prepared.
Thrombin Activation using SFB
1. SFB Activation
Molecular weight of SFB = 247.1 g/mole
According to Solulink chemistry: 4.8mgSFB/1001.11 DMSO
Prepare three different concentrations of SFB
a) Condition A: 3Oeq SFB / eq of thrombin
For inmole of thrombin 30nmoies SFB/ eq of thrombin is needed.
b) Condition B: 10eq SFB / eq of thrombin
For lnmole of thrombin lOnmoles SFB/ eq of thrombin is needed
c) Condition C: 3eq SFB / eq of thrombin
For inmole of thrombin 3nmoles SFB/ eq of thrombin is needed
Preparation of the stock solution of (SFB + DMSO):
Weigh out img of SFB and dissolve it in 20.83111 of DMSO — This gives the stock
solution X.
Since the volume of (SFB + DMSO) solution that is needed to be added to each
condition of SFB is very less Prepare a 1/100 dilution of the stock solution X: 2ptl
of (SFB + DMSO) solution + 198µl DMSO.
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Table 6.1 Dilution Series of SFB

2. Take 480n of thrombin from stock, i.e. 160m/condition of SFB or
lnmole/condition of SFB.
3. Add thrombin to each condition of SFB and incubate for 2.5 hours.
4. Post Incubation steps:
Purify the Thrombin-SFB using NAPS desalting column from Amersham
Biosciences. Take three columns for each condition of SFB. Equilibrate the
columns with 0.1M pH 6.0 PO4 buffer. The columns are first washed three times
in pH 6.0 PO4 buffer by eluting and discarding elute. Add the SFB activated
thrombin in each condition to each column.
Conjugation Reaction (Immobilization of SFB activated thrombin to SANH
activated particle): SANH + SFB reaction
1. Add 250111 of SANH-PMP to each condition of SFB activated Thrombin.
2. Separate the sample in a magnetic rack and withdraw input supernatants from
each condition.
3. Incubate overnight in shaker at room temperature (25°C — 30°C).
4. After incubation overnight the master mixture is separated in a magnetic rack and
output supernatant is withdrawn. This should give the output counts.
5. The particles is then washed three times in PBS Azide + Tween wash buffer and
then resuspended in immunoassay (PBS Azide + 2mg BSA) buffer so that the
final concentration of is particles 10mg/mi.
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6. Make a dilution series for the thrombin immobilized particle and read at a
constant voltage the fluorescence count using fluorometer.

6.2.2 Antibody Immunoassay
Experimental objective: Co-titrate Mouse anti-thrombin antibody to immobilized
thrombin followed by labeled anti-antibody (Goat anti-mouse anti-thrombin) to
determine the amount of antigen immobilized on to the particles.
Materials

Protocol
1. Wash the immobilized thrombin.
2. Add four different concentration of primary antibody, Mouse anti-thrombin.
3. Incubate overnight.
4. After incubation wash it.
5. Add three different concentration of labeled secondary antibody, Goat anti-mouse
anti-thrombin.
6. Incubate overnight.
7. After incubation wash it thoroughly.
8. Pipette it onto the microtiter plate and read it with the Fluorolite plate reader.
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6.2.3 Aptamer Binding Assay
a) Experimental objective: Thrombin Aptamer binding assay using secondary label
(Biotin-Avidin system).
Materials

Protocol
1. Immobilize thrombin on to BioMag particles using Solulink chemistry.
2. Wash the immobilized thrombin.
3. Add biotin labeled primary aptamer to the immobilized thrombin.
4. Incubate overnight.
5. Wash it after incubation.
6. Add the Avidin labeled secondary aptamer to it.
7. Incubate overnight.
8. After incubation wash thoroughly.
9. Pipette it to microtiter plate and read using plate reader.
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b) Experimental objective: Thrombin Aptamer binding assay using primary
fluorescein labeled aptamer.

Protocol

1. Immobilize thrombin on to BioMagPlus particles using Solulink chemistry.
2. Wash the immobilized thrombin.
3. Add the fluorescein labeled aptamer.
4. Incubate overnight.
5. After incubation wash thoroughly.
6. Pipette it to microtiter plate and read using plate reader.

APPENDIX A
BUFFER PREPARATIONS

This appendix contains preparation of buffers used in this research.
1. PBS Azide Wash Buffer pH 7.1 ( 1.0L)
Stock: 10 times concentrated mix of PBS Azide (10mM NaPO4, 150mM
NCI, 0.25% NaN3)
To make 1/10 dilution of stock, take 100ml of stock + 900m1 of DI water.

2. 1M Na2HPO4 Dibasic Buffer (100m1)
Weigh 26.81 gm of Na2HPO4 (Formula Weight = 268.1). Dissolve it in water
to make up 100m1.

3. 0.1M Na2HPO4 Dibasic Buffer (250m1)
Weigh 6.7gm of Na2HPO4 (Formula Weight = 268.1). Dissolve it in water to
make up 250m1.

4. 0.1M NaH2PO4 Monobasic Buffer (200m1)
Weigh 27.6gm of NaH2PO4 (Formula Weight = 138.0). Dissolve it in water to
make up 200m1

5. 10mM NaPO4 pH 8.0 Buffer (500m1)
Stock: 0.1M dibasic Na2HPO4 (pH 8.0 - 8.5), 0.1M monobasic NaH2PO4 (pH
4.5-5.0)
To 400m1 of DI water add 46.6m1 of 0.1M Na2HPO4 and 3.4m1 of 0.1M
NaH2PO4. Test the pH of the resulting buffer. Adjust the pH to 8.0 by adding
NaOH or HC1 or DI water. Bring the total buffer volume to 500m1.

6. 10mM NaPO4 pH 7.4 Buffer (250m1)
Stock: 0.1M dibasic Na2HPO4 (pH 8.0 - 8.5), 0.1M monobasic NaH2PO4 (pH
4.5-5.0)
To 200m1 of DI water add 19.35ml of 0.1M Na2HPO4 and 5.65ml of 0.1M
NaH2PO4. Test the pH of the resulting buffer. Adjust the pH to 7.4 by adding
NaOH or HC1 or DI water. Bring the total buffer volume to 250m1.
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7. Coating Buffer - 10mM NaPO4 pH 7.0 (250m1)

Stock: 0.1M dibasic Na2HPO4 (pH 8.0 - 8.5), 0.1M monobasic NaH2PO4 (pH
4.5-5.0)
To 200m1 of DI water add 14.425m1 of 0.1M Na2HPO4 and 10.575mi of 0.1M
NaH2PO4. Test the pH of the resulting buffer. Adjust the pH to 7.0 by adding
NaOH or HC1 or DI water. Bring the total buffer volume to 250m1.

8. Blocking Buffer = PBS Azide + 2mg/m1 BSA (No Tween)(250m1)

Mix 500mg of BSA in 240m1 of PBS Azide buffer. Adjust the pH to 7.1 and
then bring up the volume to 250m1.

9. Immunoassay Wash Buffer = 10mM NaPO4 (pH 7.0) +150mM Nail +

0.025% NaN3 + 0.05% Tween 20. ( pH 7.1)
Preparation of 1% Tween 20 spiking stock: Take 15m1 centrifuge tube and
pour 10m1 of DI water into the tube. Pipette 100111 of stock Tween 20 into the
10m1 DI water.
Wash buffer: PBS Azide + 0.05% Tween 20.
To 570m1 of PBS Azide buffer, add 30m1 of 1% spiking Tween 20 stock. Mix
well.

10. Assay Buffer = Immunoassay wash buffer + 2mg/ml BSA (pH 7.1)(250m1)

Mix 500mg of BSA in 240ml of Wash buffer (PBS Azide + Tween). Adjust
the pH to 7.1 and then bring up the volume to 250mi

11. Reading Buffer = 10mM NaPO4 (pH 7.42)

12. 10mM Tris Buffer pH 7.5 ( 1.0L)

Add 1.211g of Trizma Base (Tris [hydromethyl amino methane, Formula
Weight = 121.1) to 900m1 of DI water. Mix it well and pH to 8.5. Add
35.064gm of Nail (Formula Weight = 58.44) to it. Mix well and pH tolO.0.
This gives 10mM Trizma Base + 0.6M Nails. Titrate the pH down to 7.5.

13. Hybridization Buffer

Stock: 10mM Trizma Base + 0.6M Nail (pH 7.5), 2.5% Azide
(1gm/100cc), 1% BSA (1gm/100cc), 0.25% Tween 20.
Mix 148m1 of 10mM Trizma Base + 0.6M Nail (pH 7.5), 1.5m1 of Azide,
1.5gm of BSA and 0.375ml of Tween 20.

APPENDIX B
MATERIALS AND REAGENTS USED

This appendix contains the materials and reagents used for this research.
1. Bovine Serum Albumin(BSA): Fraction V, Minimum 96%; Sigma P No#
A2153-50G; Batch #063K0778

2. BioMagPlus Amine Coupling Kit; Polysciences Inc.
a. BioMagPlus Amine Terminated Particles (50mg/m1 in lmM sodium
EDTA, pH 7.0) 25m1 PNo# 86001-25 Lot#530096
b. Glutaraldehyde (EM Grade, 25%) PNo# 01909A; Lot#527456
Stock Glutaraldehyde (GA) was aiiquoted for long time storage at -20° i
in 1.5m1 eppendorff tubes. 19 aliquots 0.5ml and 1 aliquot at 2004

3. MIgG
[MIgG] = 10mg at 6.3mg/ml + 0.1%NaN3
Lot # 500-70035, iode# M8-G10

4. Goat Anti-Mouse IgG Sensilight PBXL-1
[GAM-PBXL] = lmg/ml, Lot#iS11MF01

5. Thrombin from human plasma
250 units
T-7572
Sigma Lot#102K7775, Ei No. 232-648-7
Lyophilized 1.4mg solid, 184units/mg solid, 566units/mg protein (Biuret)
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APPENDIX C
EQUIPMENT AND INSTRUMENTS USED

This appendix contains the instruments used in this research.
1) Beckman DU 520 General purpose UV/Vi Spectrophotometer
2) Fluorite 1000 Microtiter Plate reader
3) pH Meter
4) Mettler H20 Weight balance
5) Vortex- Genie; Scientific Industries Model: k550G
6) 96 well plate Magnet

APPENDIX D
GLOSSARY

This appendix contains the glossary of the terms used in this thesis report.

1. Affinity: The tendency of a molecule to associate with another. The affinity of a
drug is its ability to bind to its biological target (receptor, enzyme, transport
system, etc.) For pharmacological receptors it can be thought of as the frequency
with which the drug, when brought into the proximity of a receptor by diffusion,
will reside at a position of minimum free energy within the force field of that
receptor.

2. Antibody: A protein (immunoglobulin) produced by the immune system of an
organism in response to exposure to a foreign molecule (antigen) and characterized
by its specific binding to a site of that molecule (antigenic determinant or epitope).

3. Antigen: A compound (protein, polysaccharide, microorganism, virus) foreign to
the body that induces the production of specific antibodies.

4. Antibody affinity: A measure of the binding strength between antibody and a
simple hapten or antigen determinant. It depends on the closeness of
stereochemical fit between antibody combining sites and antigen determinants, on
the size of the area of contact between them, and on the distribution of charged and
hydrophobic groups. It includes the concept of "avidity," which refers to the
strength of the antigen- antibody bond after formation of reversible complexes.

5. Aptamer: A synthetic, specially designed oligonucleotide with the ability to
recognize and bind a protein ligand molecule or molecules with high affinity and
specificity.

6. Assay: A set of operations having the object of determining the value of a quantity.
7. Binding site: A specific region (or atom) in a molecular entity that is capable of
entering into a stabilizing interaction with another molecular entity.
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8. Bioassay: A procedure for determining the concentration or biological activity of a
substance (e.g. vitamin, hormone, plant growth factor, antibiotic, enzyme) by
measuring its effect compared with a standard preparation.
9. Enzymes: Macromolecules, mostly of protein nature, that functions as (bio)
catalysts by increasing the reaction rates. In general, an enzyme catalyses only one
reaction type (reaction specificity) and operates on only one type of substrate
(substrate specificity). A substance (usually a protein) that speeds up, or catalyzes,
a chemical reaction without being permanently altered or consumed.

10. Hybridization: The formation of stable duplexes of two DNA and/ or RNA
(complementary) strands via Watson- irick base pairing used for locating or
identifying nucleotide sequences and to establish the effective transfer of nucleic
acid material to a new host.

11. Hydrophobic: Repels water.
12. Immunoassay: A ligand- binding assay that uses a specific antigen or antibody,
capable of binding to the analyte, to identify and quantify substances. The antibody
can be linked to a radioisotope, or to an enzyme which catalyses an easily
monitored reaction (enzyme- linked immunosorbent assay, ELISA), or to a highly
fluorescent compound by which the location of an antigen can be visualized
(immunofluorescence). It is the only method possible for small molecular weight
antigens, such as steroids, drugs, lipids, and peptides. There are three basic
components in any immunoassay, the antigen to be detected and/or quantified, a
specific antibody to this antigen, and a system to measure the amount of the antigen
in the sample. The separation at the end of the immunological reaction uses a
microplate.
13. Immunoglobulin, Ig: A protein of the globulin- type found in serum or other body
fluids that possesses antibody activity. An individual Ig molecule is built up from
two light (L) and two heavy (H) polypeptide chains linked together by disulfide
bonds. Igs are divided into five classes based on antigenic and structural differences
in the H chains.
14. Ligand: A molecule which binds to a receptor protein. Any molecule that binds to
the surface of another molecule such as an immune cell receptor.
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15. Molarity: The molar unit is probably the most commonly used chemical unit of
measurement. Molarity is the number of moles of a solute dissolved in a liter of
solvent.

16. Molecular beacons: Oligonucleotide probes that can report the presence of specific
nucleic acids in homogeneous solutions (Tyagi and Kramer 1996). They are useful
in situations where it is either not possible or desirable to isolate the probe-target
hybrids from an excess of the hybridization probes, such as in real- time monitoring
of polymerase chain reactions in sealed tubes or in detection of RNAs within living
cells. Molecular beacons are hairpin- shaped molecules with an internally quenched
fluorophore whose fluorescence is restored when they bind to a target nucleic acid.

17. Nucleic acid probes: Nucleic acid which complements a specific mRNA or DNA
molecule or fragment thereof; used for hybridization studies in order to identify
microorganisms and for genetic studies.

18. Polymerase Chain Reaction(PCR): The most sensitive technique to amplify and
detect low abundance mRNA and minute amounts of DNA.

19. Probes: A specific DNA or RNA sequence which has been labeled by radioactivity,
fluorescence labels or chemiluminescence labels and which is used to detect
complementary sequences by hybridization techniques, such as blotting or colony
hybridization.

20. Peptides: Amides derived from two or more amino carboxylic acid molecules (the
same or different) by formation of a covalent bond from the carbonyl carbon of one
to the nitrogen atom of another with formal loss of water. Typically a peptide
consists of less than 50 amino acids while a protein has greater than 50 amino
acids. Peptides are ubiquitous and are found in most biological systems. In general,
peptides are synthesized by chemical techniques.

21. Proteins: Naturally occurring and synthetic polypeptides having molecular weights
greater than about 10,000 (the limit is not precise). Polymers of amino acids linked
by peptide bonds. The specific sequence of amino acids determines the shape and
function of the protein. Proteins provide the critical link between genes and disease,
and as such are the key to understanding of basic biological processes including
disease pathology, diagnosis, and treatment.
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22. Receptor: A protein or a protein complex in or on a cell that specifically recognizes
and binds to a compound acting as a molecular messenger. In a broader sense, the
term receptor is often used as a synonym for any specific (as opposed to nonspecific such as binding to plasma proteins) drug binding site, also including
nucleic acids such as DNA.

APPENDIX E
DATA SHEETS

This appendix contains the data sheets for the BioMagPlus particles used as substrates
from the Polysciences Inc. and the data sheet for Goat Anti-Mouse.

Introduction
BioMagPlus superparamagnetic microparticles are utilized in the magnetic separation of
cells, organelles, proteins, immunoglobulins, nucleic acids, and many other types of
molecules in biological and non-biological systems. The irregular shape of the
BioMagPlus particle allows for much greater surface area 20 to 30 times that of the same
size spherical particle. This large surface area results in high binding capacities, allowing
efficient target capture with minimal amounts of particles.
BioMagPlus particles are approximately one micron superparamagnetic particles
consisting of an iron oxide core with a silane coating. BioMagPlus particles are similar to
conventional BioMag particles with the important distinctions of being much more
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uniform in size and more magnetically responsive. The more uniform size results in a
more predictable and consistent behavior during capture and magnetic separation steps.
Greater magnetic responsiveness results in faster magnetic separations especially on high
throughput automated platforms.
BioMagPlus Amine particles offer a high level of amine functionality on
magnetically responsive particles. Typically the primary amine groups on the surface of
the particles are activated by glutaraldehyde, allowing amine groups on proteins to be
covalently attached.

Polysciences offers the BioMagPlus Amine Particle Protein ioupling Starter Kit
for covalently coupling proteins to BioMagPlus superpararnagnetic particles. The
contents of the kit are sufficient for five coupling reactions. To use the kit for smaller orlarger samples adjust all volumes in a proportional manner.
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Coupling Procedure
BioMagPlus Activation (Perform all activation and coupling reactions in a ventilated
chemical fume hood.)
*Note: Dilute Pyridine Wash Buffer (PWB) and Wash Buffer 1:10 with water
before using. Dilute 25% Glutaraldehyde to 5% with PWB before using.
BioMagPlus Activation
1. Transfer 5ml of BioMagPlus Amine Terminated Particles (equivalent to 250mg)
to a 50m1 conical centrifuge tube.
2. Add 40m1 of Pyridine Wash Buffer (PWB) to the flask and shake well to mix.
Magnetically separate the particles until the supernatant is clear. Aspirate the
supernatant and discard.
3. Repeat step #2 three times for a total of four washes.
4. If not done already dilute 25% glutaraldehyde to 5% with PWB. Add 20m I of 5%
glutaraldehyde to the particles and shake vigorously to mix.
5. Place the flask on a non-magnetic mixing device (rotator) for 3 hours at room
temperature. Note: The particles should not be allowed to settle during mixing.
6. Magnetically separate the activated particles until the supernatant is clear.
Aspirate the supernatant and discard.
7. Repeat Step #2 four times.
Protein Coupling
1. ialculate the amount of protein, antibody, or other ligand required for coupling.
Generally, total protein concentrations of 50 to 500pg should be used for each
milligram of activated BioMagPlus Amine Terminated Particles. iarrier proteins
such as Bovine Serum Albumin (BSA) Fraction V (PIN 23854-10) may be added
to increase total protein concentration, blocking, and provide proper orientation of
specific ligand binding for covalent attachment.
2. Dissolve the protein in 20m1 PWB.
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3. Remove 50p1 of diluted protein solution and add it to 950p1 of PWB. This is a
1:20 dilution. If further dilution is necessary dilute accordingly. Set aside in a
sealed tube for coupling efficiency determination (Pre-ioupling sample for
ioupling Efficiency Determination below.)
4. Add the remaining protein solution to the activated particles and shake vigorously
to mix. Place the flask on a mixing device for 16 to 24 hours at room temperature.
5. Magnetically separate the coupled particles until the supernatant is clear, remove,
and set aside for coupling efficiency determination. (Post-ioupling sample for
ioupling Efficiency Determination below.) If necessary dilute accordingly.
6. Resuspend the particles in 40m1 of PWB.
7. Add 20m1 of Quenching Solution. Shake vigorously to mix. Place the flask on a
mixing device for 30 minutes at room temperature.
8. Magnetically separate the particles until the supernatant is clear.' Aspirate the
supernatant and discard.
Washing and Diluting Coupled BioMagPlus Particles

1. Add 40ml of Wash Buffer and shake vigorously to mix. Magnetically separate the
particles until the supernatant is 'clear. Aspirate the supernatant and discard.
2. Repeat Step #1 three more times.
3. Resuspend the particles to 50m1 in wash buffer. Particle concentration is now
approximately 5mg/mi. Store the coupled BioMagPlus particles at 4°i as a
suspension in Wash Buffer or in a buffer that is compatible with the attached
protein.
Coupling Efficiency Determination

1. Set up a UV/Vis spectrophotometer to measure at 280nm. Fill both cuvettes with
PWB and blank the spectrophotometer.
2. Measure the absorbance of the Pre-ioupling and Post-ioupling Protein samples.
Note: Further dilutions may be necessary to read the absorbance within the linear
range of the instrument.
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3. ialculate the coupling efficiency, expressed as the % Protein Uptake as follows:
(0D280nm Pre-Coupling Sample x Dilution) - (0D280nm Post-Coupling Sample x Dilution) x 100
(0D280nm Pre-Coupling Solution x Dilution)

4. Acceptable values of % Protein Uptake are 60% to 100%.
Notes:
A. Phosphate Buffer (0.01 M, pH 7.0) can be used as a ioupling Buffer, but with
reduced coupling efficiency compared to the recommended pyridine buffer. The
polyvalent, negative phosphate ions clump the positively charged amine support.
Do not use primary amines, ammonium ion, or other strong nucleophiles in the
coupling buffer. All ioupling Buffers should be used at minimal ionic strengths.
Buffers containing amines (e.g. Tris) or phosphate buffers (e.g. PBS) can be used
as Wash Buffers. Ionic strength has little or no effect on BioMagPlus particles
once protein is attached.
B. Some noncovalent adsorption invariably accompanies covalent coupling to
particulate supports. Noncovalent adsorption is controlled by the washing
procedure used after covalent protein attachment. The degree of noncovalent
adsorption varies with each application and the washing procedure may have to be
adjusted for individual applications. Additional washes to reduce non-covalently
adsorbed protein can include high salt (1M NaiI), mildly acidic or basic media,
mildly elevated temperatures, or increased time of exposure to the Wash Buffer.
Dissociation of active, non-covalently adsorbed molecules from BioMagPlus
particles can make magnetic materials appear unstable in some applications.
i. Prolonged vigorous shaking or sonication should be used to resuspend
BioMagPlus particles after magnetic separation or settling with gravity.

Storage and Handling Information
Freezing, drying, or centrifuging BioMagPlus particles result in extensive aggregation
and loss of binding activity. DO NOT FREEZE OR DRY BioMagPlus Particles. Store
BioMagPlus particles and the liquid contents of the ioupling Kit at 4°i.
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Researchers are advised to optimize the use of BioMagPlus particles in any application as
procedures designed by other manufacturers may not be ideal.

For research use only, not intended for use in humans or in vitro diagnostics use.
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